Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Efkarpia – page 12

680 clinical trials in Efkarpia, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Efkarpia at a glance
680
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

680 trials in Efkarpia

Open in trial search

K-ras gene mutation+2

Recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Dementia Alzheimer's type

Recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for treating agitation in Alzheimer's disease patients

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Asthma

Recruiting

Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Myasthenia gravis

Recruiting

Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Colitis ulcerative

Recruiting

Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

Investigational
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary arterial hypertension

Recruiting

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:LTP001
  • Sponsor:Novartis Pharma AG

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Efkarpia

What the registry says about research in the country

01 Dermatology Research

Extensive trials focusing on hidradenitis suppurativa and atopic dermatitis, evaluating novel therapeutic approaches and treatment combinations to improve patient outcomes.

  • Chronic skin conditions
  • Inflammatory disorders
  • Autoimmune skin diseases

Multiple studies testing new biological therapies and their long-term safety profiles.

02 Autoimmune Conditions

Research centered on lupus erythematosus and Sjögren's Disease, investigating targeted therapies to manage disease progression and symptoms.

  • Systemic autoimmune diseases
  • Novel immunological treatments
  • Disease activity markers

Studies aim to evaluate new therapeutic agents for better disease control.

03 Metabolic Disorders

Innovative trials examining treatments for Type 2 Diabetes and obesity, with focus on cardiovascular outcomes and weight management.

  • Diabetes management
  • Weight control therapies
  • Cardiovascular risk reduction

Research comparing new therapeutic options against established treatments.

04 Oncology Studies

Advanced research in metastatic breast cancer and colorectal cancer, evaluating targeted therapies and combination treatments.

  • HER2-positive cancers
  • Treatment resistance
  • Combination therapies

Focus on improving progression-free survival in advanced disease stages.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.